133
34. Anderson JL, Muhlestein JB. Antibiotic trials for coronary heart disease. Tex Heart Inst J.
2004;31(1):33–8.
35. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass
M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103(3):351–6.
36. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease
events. Circulation. 1999;99(12):1538–9.
37. Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989;33(9):1634–5.
8 Antibiotic Resistance in EDCs-Induced Metabolic Disorders
34. Anderson JL, Muhlestein JB. Antibiotic trials for coronary heart disease. Tex Heart Inst J.
2004;31(1):33–8.
35. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass
M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001;103(3):351–6.
36. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease
events. Circulation. 1999;99(12):1538–9.
37. Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother. 1989;33(9):1634–5.
8 Antibiotic Resistance in EDCs-Induced Metabolic Disorders